key: cord-0926759-w9m5g4u2
authors: Waldman, Reid A.; Creed, Marina; Sharp, Kelley; Adalsteinnson, Jonas; Imitola, Jaime; Durso, Timothy; Lu, Jun
title: Letter in Reply: Toward a COVID-19 Vaccine Strategy for Pemphigus Patients on Rituximab
date: 2020-10-29
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.10.075
sha: fc45914a1da4df914710ca3c9e3c496034c4506e
doc_id: 926759
cord_uid: w9m5g4u2

nan

peripheral B-cell depletion on future COVID-19 vaccine response. Their articles highlight the 27 need for emergent study of anti-CD20 therapy's impact on COVID-19 vaccine response. Herein, 28 we review existing data surrounding vaccination of individuals receiving anti-CD20 monoclonal 29 antibodies.

The effect of rituximab and other anti-CD20 monoclonal antibodies on vaccine response 31 has been studied for inactivated vaccines including seasonal influenza, hepatitis B, tetanus, 32 shingles, pneumococcus, and Haemophilus influenza B. 1,2 These studies suggest that rituximab 33 recipients mount attenuated, yet meaningful vaccine responses. 1 Additionally, these studies While vaccine response may be attenuated and may occur at lower rates in rituximab recipients, 63 vaccine response can be quantified with titers which may be helpful for guiding decisions to 64 revaccinate patients following humoral immune reconstitution (~6-9 months after rituximab

COVID-19 vaccine-readiness for anti-CD20-73 depleting therapy in autoimmune diseases

Could anti-CD20 therapy jeopardise the efficacy of 76 a SARS-CoV-2 vaccine?

Immunizations 78 in immunocompromised patients: a guide for dermatologists

Effect of ocrelizumab on vaccine responses in 81 patients with multiple sclerosis: The VELOCE study

mRNA vaccines -a new era in vaccinology